The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.
The FDA approved mavacamten (Camzyos), a cardiac myosin inhibitor, for the treatment of adult patients with New York Heart Association class II to III obstructive hypertrophic cardiomyopathy (HCM) in 2022. Milind Desai, MD, MBA, Cleveland Clinic, reported on the drug’s safety profile and efficacy at this year’s American Heart Association (AHA) Scientific Sessions. At present, he was able to speak to the real-world, 22-month data on mavacamten and the role of a risk evaluation and mitigation strategy (REMS) program for monitoring patients.
Desai discussed in more detail the process of implementing the REMS program, which their findings suggest was a valuable tool in assessing the benefits of mavacamten and its ability to improve patients’ functional lung capacity and other associated disease symptoms.
This transcript has been lightly edited for clarity and length.
Transcript
What have been the main challenges or successes in implementing the REMS monitoring for patients on mavacamten, and how has it influenced the overall safety profile in real-world use?
So the REMS program, or the risk evaluation mitigation strategy program, is something that the FDA mandates in situations where they want to ensure safety of a new drug in a postapproval phase when it is marketed to a broader audience, a broader group of patients. They want to emphasize that there is convincing follow-up in terms of beyond what a package insert can offer, so clearly, not every drug gets the REMS labeling, and not every provider is well-versed with the REMS program.
So the biggest initial challenge was [providers asking,] “What is it? How do we incorporate that in our practice? How do we operationalize this? How do we explain it to the patients?” in addition to all the challenges that come with launching or rather trialing a new drug. I think those were the initial challenges. Most places, most larger HCM centers, have learned to develop the robust processes that work in terms of implementing the REMS program, including working with the specialty pharmacies, including making the patients understand, and including making themselves—the providers, as well as their teams—understand. So, I think it was a major, steep learning curve. And pretty much the ones that use mavacamten frequently have gotten used to it, and, to use a golfing term now, it's pretty much par for the course in a lot of places.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More